{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:05Z","timestamp":1794047465617,"version":"4.8.0"},"reference-count":19,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281396","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:23:25Z","timestamp":1712805805000},"page":"2653-2659","source":"Crossref","is-referenced-by-count":2,"title":["Molecular responses in decitabine- and decitabine\/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes"],"prefix":"10.3324","volume":"109","author":[{"given":"Agata","family":"Gruszczynska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Mukund","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allegra A.","family":"Petti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kala","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"64873","doi-asserted-by":"crossref","unstructured":"Welch JS, Petti AA, Miller CA. TP53 and decitabine in acute myeloid leukemia and myelodysplastic Syndromes. N Engl J Med. 2016; 375(21):2023-2036.","DOI":"10.1056\/NEJMoa1605949"},{"key":"64874","doi-asserted-by":"crossref","unstructured":"Kim K, Maiti A, Loghavi S. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021; 127(20):3772-3781.","DOI":"10.1002\/cncr.33689"},{"key":"64875","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Maiti A, Rausch CR. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020; 7(10):e724-e736.","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"64876","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018; 378(13):1189-1199.","DOI":"10.1056\/NEJMoa1716863"},{"key":"64877","doi-asserted-by":"crossref","unstructured":"Duncavage EJ, Uy GL, Petti AA. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood. 2017; 129(10):1397-1401.","DOI":"10.1182\/blood-2016-10-745273"},{"key":"64878","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"64879","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, Loghavi S, Furudate K. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021; 5(8):2173-2183.","DOI":"10.1182\/bloodadvances.2020004173"},{"key":"64880","doi-asserted-by":"crossref","unstructured":"Zavras PD, Shastri A, Goldfinger M, Verma AK, Saunthararajah Y. Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions. Clin Cancer Res. 2021; 27(24):6653-6661.","DOI":"10.1158\/1078-0432.CCR-21-2139"},{"key":"64881","doi-asserted-by":"crossref","unstructured":"Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464.","DOI":"10.1056\/NEJMoa1614359"},{"key":"64882","doi-asserted-by":"crossref","unstructured":"Gianfaldoni G, Mannelli F, Intermesoli T. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Blood Adv. 2020; 4(2):301-311.","DOI":"10.1182\/bloodadvances.2019000406"},{"key":"64883","doi-asserted-by":"crossref","unstructured":"Yun S, Geyer SM, Komrokji RS. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021; 35(4):1145-1155.","DOI":"10.1038\/s41375-020-0997-4"},{"key":"64884","doi-asserted-by":"crossref","unstructured":"Hunter AM, Komrokji RS, Yun S. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021; 5(4):1017-1028.","DOI":"10.1182\/bloodadvances.2020003508"},{"key":"64885","doi-asserted-by":"crossref","unstructured":"Illman J, Kytola S, Myllymaki M, Ebeling F. Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome. Haematologica. 2023; 108(7):1951-1956.","DOI":"10.3324\/haematol.2022.281595"},{"key":"64886","doi-asserted-by":"crossref","unstructured":"Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017; 12(2):79-84.","DOI":"10.1007\/s11899-017-0375-0"},{"key":"64887","doi-asserted-by":"crossref","unstructured":"Yilmaz M, Kantarjian H, Wang X. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020; 95(2):144-150.","DOI":"10.1002\/ajh.25671"},{"key":"64888","doi-asserted-by":"crossref","unstructured":"Gui G, Hourigan CS. Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia. Cancer J. 2022; 28(1):73-77.","DOI":"10.1097\/PPO.0000000000000572"},{"key":"64889","doi-asserted-by":"crossref","unstructured":"Colmenares R, Alvarez N, Barrio S, Martinez-Lopez J, Ayala R. The minimal residual disease using liquid biopsies in hematological malignancies. Cancers (Basel). 2022; 14(5):1310.","DOI":"10.3390\/cancers14051310"},{"key":"64890","doi-asserted-by":"crossref","unstructured":"Jansko-Gadermeir B, Leisch M, Gassner FJ. Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT Study Group. Cancers (Basel). 2023; 15(8):2305.","DOI":"10.3390\/cancers15082305"},{"key":"64891","doi-asserted-by":"crossref","unstructured":"Lucas F, Michaels PD, Wang D, Kim AS. Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing. Blood Adv. 2020; 4(18):4362-4365.","DOI":"10.1182\/bloodadvances.2020002306"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281396\/76860","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281396\/77356","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11552\/76860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:12Z","timestamp":1794045972000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281396","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}